Preoperative versus postoperative treatment for locally advanced rectal carcinoma

Future Oncology

Volumn 1, Issue 2, 2005, Pages 209-220

  Pasetto, Lara Maria ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

adjuvant; chemoradiotherapy; neoadjuvant; rectal cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; CLINICAL TRIAL; FORECASTING; HUMAN; METASTASIS; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; POSTOPERATIVE CARE; PREOPERATIVE CARE; RECTUM TUMOR; REVIEW;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; FORECASTING; HUMANS; NEOPLASM METASTASIS; POSTOPERATIVE CARE; PREOPERATIVE CARE; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS;

EID: 33646449852     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.1517/14796694.1.2.209     Document Type: Review

References (83)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics 1999. Cancer J. Clin. 49, 8-31 (1999)
2. AJCC American Joint Committee on Cancer. In:AJCC Cancer Staging Manual, 5th ed. Fleming DI, Coper SJ, Henson ED et al. (Eds). Lippincott-Raven, Philadelphia-New York, USA, 83-90 (1997)
3. NIH consensus conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 264, 1444-1450 (1990)
4. Heald RJ, Smedh RK, Kald A, Sexton R, Moran BJ: Abdominoperineal excision of the rectum - an endangered operation. Norman Nigro Lectureship. Dis. Colon Rectum 40, 747-751 (1997)
5. Kockerling F, Reymond MA, Altendorf- Hofmann A, Dworak O, Hohenberger W: Influence of surgery on metachronous distant metastases and survival in rectal cancer. J. Clin. Oncol. 16, 324-329 (1998)
6. Dahlberg M: Changing strategy for rectal cancer is associated with improved outcome. Br. J. Surg. 86 (3), 379-384 (1999)
7. Adam IJ, Mohamdee MO, Martin IG et al : Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet 344, 707-711 (1994)
8. Nagtegaal ID, Marijnen CA, Kranenbarg EK et al.: Short-term preoperative RT interferes with the determination of pathological parameters in rectal cancer. J. Pathol. 197, 20-27 (2002)
9. Swedish Rectal Cancer Trial: Improved survival with preoperative radiotherapy in resectable rectal cancer. N. Engl. J. Med. 336, 980-987 (1997)
10. Kapiteijn E, Marijnen CAM, Nagtegaal ID et al.: for the Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N. Engl. J. Med. 345, 638-646 (2001)
11. Holm T, Rutqvist LE, Johannson H, Cedrmark B: Postoperative mortality in rectal cancer treated with or without preoperative radiotherapy: causes and risk factors. Br. J. Surg. 83, 964-968 (1996)
12. Camma C, Giunta M, Fiorica F et al.: Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA 284, 1008-1015 (2000)
13. Madoff RD: Chemoradiotherapy for rectal cancer - When, Why, and How? N. Engl. J. Med. 351, 1790-1792 (2004)
14. Stockholm Colorectal Cancer Study Group: Randomized study on preoperative radiotherapy in rectal carcinoma. Ann. Surg. Oncol. 3, 423-430 (1996)
15. Dahlberg M, Glimelius B, Graf W, Pahlman L: Preoperative irradiation affects functional results after surgery for rectal cancer: results from a randomized study. Dis. Colon Rectum 41, 543-549 (1998)
16. Minsky BD: Adjuvant therapy of rectal cancer. Semin. Oncol. 26, 540-544 (1999)
17. Colorectal Cancer Collaborative Group: Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomized trials. Lancet 20, 358 (9290), 1291-1304 (2001)
18. OConnell MJ, Martenson JA, Wieand HS et al.: Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N. Engl. J. Med. 331(8), 502-507 (1994)
19. Gastrointestinal Tumor Study Group: Prolongation of the disease-free interval in surgically treated rectal carcinoma. N. Engl. J. Med. 312, 1465-1472 (1985)
20. Krook JE, Moertel CG, Gunderson LL et al.: Effective surgical adjuvant therapy for high-risk rectal carcinoma. N. Engl. J. Med. 324, 709-715 (1991)
21. Gastrointestinal Tumor Study Group: Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. J. Clin. Oncol. 10, 549-557 (1992)
22. Rodel C, Grabenbauer GG, Shick C, Papandopulos T, Hoehnberger W, Sauer R: Preoperative radiation with concurrent 5Fluorouracil for locally-advanced T4 primary rectal cancer. Strahlenther. Onkol. 176, 161-167 (2000)
23. Videtic GM, Fisher BJ, Perera FE et al.: Preoperative radiation with concurrent 5- fluorouracil continuous infusion for locally advanced unresectable rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 42(2), 319-324 (1998)
24. Chan AK, Wong AO, Langevin J et al.: Preoperative CT and pelvic radiation for tethered or fixed rectal cancer: a phase II dose escalation study. Int. J. Radiat. Oncol. Biol. Phys. 48 (3), 843-856 (2000)
25. Grann A, Feng C, Wong D et al.: Preoperative combined modality therapy for clinically resectable uT3 rectal adenocarcinoma. Int. J. Radiat. Oncol. Biol. Phys. 49, 987-995 (2001)
26. Valentini V, Coco C, Cellinin N et al.: Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, sphincter preservation in three consecutive studies. Int. J. Radiat. Oncol. Biol. Phys. 51, 371-383 (2001)
27. Moertel CG, Childs DS, Reitemeier RJ et al.: Combined 5-FU and super voltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2, 865-867 (1969)
28. Rominger Cj, Gelber RD, Gunderson LL, Conner N: Radiation therapy alone or in combination with CT in the treatment of residual or inoperable carcinoma of the rectum and recto sigmoid or pelvic recurrence following colorectal surgery. Radiation Therapy Oncology Group Study. Am. J. Clin. Oncol. 8, 118-127 (1985)
29. Overgaard M, Bertelsen K, Dalmark M et al.: A randomized feasibility study evaluating the effect of radiotherapy alone or combined with 5-FU in the treatment of locally recurrent or inoperable colorectal carcinomas. Acta Oncol. 32, 547-553 (1993)
30. Desch CE, Benson AB, Smith TJ et al.: Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. J. Clin. Oncol. 17(4), 1312 (1999)
31. Roh M, Petrelli N, Wieand S et al.: Phase III randomized trial of preoperative versus postoperative multimodality therapy in patients with carcinoma of the rectum. Proc. Am. Soc. Clin. Oncol. 20, 123a [Abstract 490] (2001)
32. Sauer R, Fietkau R, Wittekind C et al.: Adjuvant versus neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO-94. Colorectal Dis. 5(5), 406-415 (2003)
33. Frykholm GJ, Glimelius B, Pahlman L: Preoperative and postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects. Dis. Colon Rectum 36, 564-572 (1993)
34. Kollmorgen CF, Meagher AP, Wolff BG, Pemberton JH, Martenson JA, Illstrup DM: The long-term effect of adjuvant postoperative chemoradiotherapy for rectal cancer on bowel function. Ann. Surg. 220, 676-682 (1994)
35. Minsky BD, Conti JA, Huang Y, Knopf K: The relationship of acute gastrointestinal toxicity and the volume of irradiated small bowel in patients receiving combined modality therapy for rectal cancer. J. Clin. Oncol. 13, 1409-1416 (1995)
36. Chan AK, Wong AO, Langevin J et al.: Sandwich preoperative and postoperative combined chemotherapy and radiation in tethered and fixed rectal cancer: Impact of treatment intensity on local control and survival. Int. J. Radiat. Oncol. Biol. Phis. 37(3), 629-637 (1997)
37. Rich TA, Skibber JM, Ajani JA et al.: Preoperative infusional chemoradiation therapy for Stage T3 rectal cancer. Int. J. Radiat. Oncol. Biol. Phis. 32(4), 1025-1029 (1995)
38. Marsh RD, Chu NM, Vauthey JN et al.: Preoperative treatment of patients with locally advanced unresectable rectal adenocarcinoma utilizing continuous chronobiologically shaped 5-FU infusion and radiation therapy. Cancer 78, 217-225 (1996)
39. Bouzourene H, Bosman FT, Seelentag W, Matter M, Coucke P: Importance of tumour regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer 94(4), 1121-1130 (2002)
40. Rödel C, Grabenbauer GG, Papadopoulos T et al.: Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 52(2), 294-303 (2002)
41. Grann A, Minsky BD, Cohen AM et al.: Preliminary results of preoperative 5-FU, low-dose leucovorin, and concurrent radiation therapy for resectable T3 rectal cancer. Dis. Colon Rectum 40, 515-522 (1997)
42. Chari RS, Tyler DS, Anscher MS et al.: Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum. Ann. Surg. 221, 778-787 (1995)
43. Stryker SJ, Kiel KD, Rademaker A, Shaw JM, Ujiki GT, Poticha SM: Preoperative "chemoradiation" for Stages II and III rectal carcinoma. Arch. Surg. 131, 514-519 (1996)
44. Pucciarelli S, Friso ML, Toppan P et al.: Preoperative combined radiotherapy and chemotherapy for middle and lower rectal cancer: preliminary results. Ann. Surg. Oncol. 7(1), 38-44 (2000)
45. Enker WE, Merchant N, Cohen AM et al.: Safety and efficacy of low anterior resection for rectal cancer. 681 consecutive cases from a specialty service. Ann. Surg. 230, 544-554 (1999)
46. Ooi BS, Tjandra JJ, Green MD: Morbidities of adjuvant chemotherapy and radiotherapy for resectable rectal cancer. Dis. Colon Rectum 42, 403-418 (1999)
47. Paty PB, Enker WE, Cohen AM, Minsky BD, Friedlander-Klar H: Long-term functional results of coloanal anastomosis for rectal cancer. Am. J. Surg. 167, 90-95 (1994)
48. Minsky BD, Cohen AM, Kemeny N et al.: The efficacy of preoperative 5-Fluorouracil, high dose leucovorin, and sequential radiation therapy for unresectable rectal cancer. Cancer 71(11), 3486-3492 (1993)
49. Bosset JF, Pavy JJ, Hamers HP et al.: Determination of the optimal dose of 5- Fluorouracil when combined with low dose D, L-leucovorin and irradiation in rectal cancer: results of three consecutive Phase II studies. EORTC Radiotherapy Group. Eur. J. Cancer 29(10), 1406-1410 (1993)
50. Marsh RD, Chu NM, Vauthey JN et al.: Preoperative treatment of patients with locally advanced unresectable rectal adenocarcinoma utilizing continuous chronobiologically shaped 5-fluorouracil infusion and radiation therapy. Cancer 78(2), 217-225 (1996)
51. Mohiuddin M, Regine Wf, John WJ et al.: Preoperative chemoradiation in fixed distal rectal cancer: dose time factors for pathological complete response. Int. Radiat. Oncol. Biol. Phys. 46 (4), 883-888 (2000)
52. Streit M, Jaehde U, Stremetzne S et al.: Five days continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: an effective second-line regimen. Ann. Oncol. 8(11), 163-165 (1997)
53. Hartmann JT, Kohne CH, Schmoll HJ, Daikeler T, Kanz L, Bokemeyer C: Is continuous 24-hour infusion of 5- fluorouracil plus high dose folinic-acid effective in patients with progressive or recurrent colorectal cancer? A Phase II study. Oncology 55(4), 320-325 (1998)
54. Bosset JF, Calais G, Daban A et al.: EORTC Radiotherapy Group: Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance. Report of the 22921 randomized trial conducted by the EORTC Radiotherapy Group. Eur. J. Cancer. 40(2), 219-224 (2004)
55. Sauer R, Becker H, Hohenberger W et al: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med. 351, 1731-1740 (2004)
56. Chau I, Allen M, Cunningham D et al.: Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer. Br. J. Cancer 88(7), 1017-1024 (2003)
57. Valentini V, Coco C, Picciocchi A et al.: Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int. J. Radiat. Oncol. Biol. Phys. 53(3), 664-674 (2002)
58. Calvo FA, Gomez-Espi M, Diaz-Gozales JA, et al.: Pathologic downstaging of T3-4Nx rectal cancer after chemoradiation: 5Fluorouracil vs Tegafur. Int. J. Radiat. Oncol. Biol. Phys. 51(5), 1264-1270 (2001)
59. de la Torre A, Ramos S, Valcarcel EJ et al.: Phase II study of chemoradiotherapy with UFT and low doses oral leucovorin in patients with unresectable rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 45(3), 629-634 (1999)
60. Hoff PM, Janjan N, Saad ED et al.: Phase I study of preoperatory oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer. Clin. Oncol. 18(29), 3529-3534 (2000)
61. Feliu J, Calvillo J, Escribano A et al.: Neoadjuvant therapy of rectal carcinoma with UFT-leucovorin bolus radiotherapy. Ann. Oncol. 13(5), 730-736 (2002)
62. Uzcudun AE, Battle JF, Valasco JC, Sanchez Santos ME, Carpeno Jde C, Grande AG: Efficacy of preoperative radiation therapy for resectable rectal adenocarcinoma when combined with oral tegafur-uracil modulated with leucovorin: results from a Phase II study. Dis. Colon Rectum 45(10), 1349-1358 (2002)
63. Dunst J, Reese T, Sutter T et al.: Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J. Clin. Oncol. 20(19), 3983-3991 (2002)
64. Mehta VK, Cho C, Ford JM et al.: Phase II trial of preoperative 3D conformal radiotherapy protracted venous infusion 5- fluorouracil, and weekly CPT11, followed by surgery for ultrasound Staged T3 rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 55(1), 132-137 (2003)
65. Navarro M, Dotor E, Riviera F et al.: Phase II trial of irinotecan (CPT11) and 5- fluorouracil (5-FU) concomitantly with radiotherapy in patients with locally advanced resectable rectal cancer. Proc. Am. Soc. Clin. Oncol. 22, 308 [Abstract 1235] (2003)
66. Freyer G, Bossard N, Roemstaing P et al.: Addition of oxaliplatin to continuous fluorouracil, L-folinic acid, and concomitant radiotherapy in rectal cancer: The Lyon R 97-03 Phase I Trial. J. Clin. Oncol. 19(9), 2433-2438 (2001)
67. Sebag-Montefiore D: An update report on the MRC CR07 trial. Br. J. Cancer 85, S1 28 (2001)
68. Carraro S, Roca EL, Cartelli C et al.: Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin and 5-FU in T3-4 unresectable rectal cancer: a phase II IATTG1 study. Int. J. Radiat. Oncol. Biol. Phys. 54(2), 397-402 (2002)
69. Gérard JP, Chapet O, Nemoz C et al.: Preoperative concurrent radiochemotherapy in locally advanced rectal cancer with high dose radiation and oxaliplatin containing regimen: the Lyon RO-04 phase II trial. J. Clin. Oncol. 21(6), 1119-1124 (2003)
70. Sebag-Montefiore D, Glynne-Jones R, Falk S, Maughan T, Meadows H: Preoperative radiation and oxaliplatin in combination with 5-fluorouracil (5-FU) and low-dose leucovorin (LV) in locally advanced rectal cancer. Proc. Am. Soc. Clin. Oncol. 21, 146a [Abstract 580] (2002)
71. Aschele C, Friso ML, Pucciarelli S et al.: A phase I study of weekly oxaliplatin + 5- fuorouracil continuous infusion in combination with preoperative radiotherapy in locally advanced rectal cancer. Proc. Am. Soc. Clin. Oncol. 21, 132a [Abstract 527] (2002)
72. Withers HR, Haustermans K: Where next with preoperative radiation therapy for rectal cancer? Int. J. Radiat. Oncol. Biol. Phys. 58(2), 597-602 (2004)
73. Schaffer M, Thoma M, Wilkowski R, Schaffer P, Duhmke E: Radiochemotherapy as a preoperative treatment for advanced rectal cancer. Evaluation of down-staging and morbidity. Onkologie 25(4), 352-356 (2002)
74. Chen ET, Mohiuddin M, Brodovsky H, Fishbein G, Markus G: Downstaging of advanced rectal cancer following combined preoperative chemotherapy and high dose radiation. Int. J. Radiat. Oncol. Biol. Phys. 30(1), 169-175 (1994)
75. Janjan NA, Khoo VS, Abbruzzese J et al.: Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the MD Anderson cancer Center experience. Int. J. Radiat. Oncol. Biol. Phys. 44(5), 1027-1038 (1999)
76. Ngan SY, Burmeister BH, Fisher R et al.: Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the rectum: a phase II trial for the trans-Tasman Radiation Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. 50(4), 883-887 (2001)
77. Mehta VK, Poen J, Ford J et al.: Radiotherapy, concomitant protractedvenous- infusion 5-fluorouracil, and surgery for ultrasound-Staged T3 or T4 rectal cancer. Dis. Colon Rectum 45(1), 143-144 (2002)
78. Chan AK, Wong AO, Langevin J, Khoo R: Preoperative concurrent 5-fluorouracil infusion, mitomycin C and pelvic radiation therapy in tethered and fixed rectal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 25(5), 791-799 (1993)
79. Valentini V, Doglietto GB, Morganti AG et al.: Preoperative chemoradiation with raltitrexed (Tomudex) for T2N+ rectal cancers: a phase I study. Eur. J. Cancer 37(16), 2050-2055 (2001)
80. Gambacorta MA, Micciche F, Corvari B, Mantini G, Valentini V: Biological factors and therapeutic modulation in rectal cancer radiotherapy. Rays 27(3), 219-222 (2002)
81. Kim JS, Kim JS, Cho MJ, Song KS, Yoon WH: Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 54(2), 403-408 (2002)
82. Ku JL, Yoon KA, Kim DY, Park JG: Mutations in hMSH6 alone are not sufficient to cause the microsatellite instability in colorectal cancer cell lines. Eur. J. Cancer 35(12), 1724-1729 (1999)
83. Lawrence TS, Blackstock AW, McGinn C: The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin. Radiat. Oncol. 13, 13-21 (2003)